Clinical Trial Update: Multicenter Trial of Immunotherapy With House Dust Mite Allergoid [Phase 3]

View source ↗

Summary

A multicenter Phase 3 trial evaluating immunotherapy with House Dust Mite Allergoid for rhinoconjunctivitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rhinoconjunctivitis

Drugs mentioned

• House Dust Mite Allergoid (house dust mite allergoid extract)

Snippet

Sponsor: Allergopharma GmbH & Co. KG | Conditions: Rhinoconjunctivitis | Phase 3 | Status: COMPLETED